Education
About Us
Working with TipRanks
Follow Us
Inventiva (IVA)
NASDAQ:IVA
IVA Stock Chart & Stats
$6.09
-$0.02(-0.90%)
At close: 4:00 PM EST
$6.09
-$0.02(-0.90%)
Day’s Range― - ―
52-Week Range$2.67 - $7.98
Previous CloseN/A
Volume917.00
Average Volume (3M)99.38K
Market Cap
$1.23B
Enterprise Value$642.88M
Total Cash (Recent Filing)$122.08M
Total Debt (Recent Filing)$57.13M
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Mar 30, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding207,707,470
10 Day Avg. Volume175,727
30 Day Avg. Volume99,378
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-1.01
Price to Sales (P/S)11.68
P/FCF Ratio-1.25
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue58.88
Enterprise Value/Gross Profit66.00
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$16.50Price Target Upside170.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$2.77M
Bulls Say, Bears Say
Bulls Say
Efficacy And Safety ProfileSynergistic metabolic benefits in preclinical models, including weight reduction, lower food intake, improved glycemic control, and enhanced cardiac performance without common PPAR-related side effects, indicate a potentially favorable benefit-risk profile.
Mechanism ValidationExternal validation from a unimolecular quintuple agonist that combines incretin targeting with lanifibranor's pan-PPAR activity supports confidence in Inventiva's therapeutic approach and platform strategy.
Phase 3 Design And Commercial PotentialA larger, longer Phase 3 trial with an enriched population increases the likelihood of demonstrating deeper histologic benefit and strengthens the case for lanifibranor as an oral monotherapy or combination option in the sizable MASH market.
Bears Say
Commercial Outlook UncertaintyNew entrant activity creates uncertainty around longer-term commercial adoption and pricing dynamics for an oral pan-PPAR therapy in the MASH space.
Competitive ThreatEmergence of a new biotech developing the same five-receptor mechanism raises competitive risk that could challenge lanifibranor's market positioning.
Differentiation And Evidentiary DemandsOverlap in mechanism with a competing program could force a need for additional clinical differentiation or head-to-head evidence to secure regulatory approvals and payer support.
Inventiva News
IVA FAQ
What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was $2.67 and its highest was $7.98 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is $1.23B.
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Mar 30, 2026 which is in 26 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Sep 29, 2025. The company reported -$1.616 earnings per share for the quarter, missing the consensus estimate of -$0.63 by -$0.986.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.28.
How many shares outstanding does Inventiva have?
Inventiva has 207,707,470 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -$1.616 in its last earnings report, missing expectations of -$0.63. Following the earnings report the stock price went down -2.975%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inventiva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.50 (170.94% Upside)
$16.50 (170.94% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
399.59%
Trailing 12-Months
Company Description
Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
IVA Stock 12 Month Forecast
Average Price Target
$16.50
▲(170.94% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Urogen Pharma
―
Maravai Lifesciences Holdings
―
MBX Biosciences, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
17.57% Other Institutional Investors
82.31% Public Companies and Individual Investors
Options Prices
Currently, No data available
---